Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Parkinson’s disease is a disorder of the nervous system causing tremor, stiffness and slowness of movement. The main problem for clinicians is that it’s very hard to diagnose Parkinson’s early enough to offer patients beneficial treatment. By the time they show up in clinic, the disease is already advancing and it is only the symptoms which can be managed, rather than the cause addressed.

My aim is to identify the people with RBD who are at the highest risk of developing Parkinson’s before their symptoms appear. If we can do this, it may allow us to start them on treatment to slow down or even prevent the onset of Parkinson’s.
- Michele Hu

The Oxford Parkinson’s Disease Centre, led by Consultant Neurologist Professor Michele Hu alongside Professor Richard Wade-Martins, is making great strides forward on many fronts in the struggle to understand this condition. Most recently, they have been awarded a five-year grant from the NIHR Oxford Biomedical Research Centre to look into the relationship between Parkinson’s and a sleep condition known as Rapid Eye Movement Sleep Behaviour Disorder (or RBD for short). In RBD, the switch that normally turns off movement during sleep is faulty, causing people to move or shout while asleep.

Sleep disorders are interesting for neurologists because they can be an early indicator of problems with the nervous system. Michele and her colleagues are particularly focusing on the link between RBD and Parkinson’s because many people with Parkinson’s are thought to suffer from RBD as well. A person who goes on to develop Parkinson’s may have RBD for many years before the problems begin with their movement when they are awake. So might it be possible to use RBD as a sort of ‘biomarker’ for Parkinson’s?

The first step for the research team is to invite people who are already coming into clinic for an NHS sleep study to wear some new kit at the same time. The recording equipment includes a motion sensor worn on the wrist, a pulse and oxygen sensor worn on a fingertip, and a sleep monitoring device which worn on the head, chest and abdomen. Michele and colleagues in the Oxford Institute of Biomedical Engineering will ‘train’ computer algorithms to correctly interpret the data that the wearable kit collects. The team then hope to recruit people from across the UK who have either RBD or Parkinson’s, to wear the sleep monitoring devices at home for a few nights every six months.

Similar stories

European Platform for Neurodegenerative Diseases launches repository of cohorts for researchers

The new Cohort Catalogue will facilitate discovery of over 60 neurodegeneration research cohorts from 17 countries across Europe

Ashmolean turns red for World Encephalitis Day

Our researchers are tackling the devastating brain condition encephalitis.

Bioelectronic implant offers an intelligent therapy to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their 'smart' bioelectronic implants.

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.